Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BLB-201 Phase 1 in healthy adults
NCT05281263Phase 1Completed
- Sponsor
- Blue Lake Biotechnology
- Start
- Jul 2022
- Primary completion
- Dec 2022
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of BLB-201 in respiratory syncytial virus infection (RSV) (2 arms), sponsored by Blue Lake Biotechnology. Primary endpoints: Solicited Adverse Events and Unsolicited Adverse Events. Started Jul 2022; status: completed.
02
Drugs
BLB-201
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT05281263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05281263.